444 related articles for article (PubMed ID: 33233320)
1. Therapeutic Potential of PARP Inhibitors in the Treatment of Metastatic Castration-Resistant Prostate Cancer.
Jang A; Sartor O; Barata PC; Paller CJ
Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33233320
[TBL] [Abstract][Full Text] [Related]
2. When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials.
Antonarakis ES; Gomella LG; Petrylak DP
Eur Urol Oncol; 2020 Oct; 3(5):594-611. PubMed ID: 32814685
[TBL] [Abstract][Full Text] [Related]
3. PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: Unraveling the Therapeutic Landscape.
Al-Akhras A; Hage Chehade C; Narang A; Swami U
Life (Basel); 2024 Jan; 14(2):. PubMed ID: 38398706
[TBL] [Abstract][Full Text] [Related]
4. Clinical Application of Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Prostate Cancer.
Inderjeeth AJ; Topp M; Sanij E; Castro E; Sandhu S
Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497408
[TBL] [Abstract][Full Text] [Related]
5. Clinical Development of PARP Inhibitors in Treating Metastatic Castration-Resistant Prostate Cancer.
Adashek JJ; Jain RK; Zhang J
Cells; 2019 Aug; 8(8):. PubMed ID: 31404966
[TBL] [Abstract][Full Text] [Related]
6. The Role of PARP Inhibitors in the Treatment of Prostate Cancer: Recent Advances in Clinical Trials.
Xia M; Guo Z; Hu Z
Biomolecules; 2021 May; 11(5):. PubMed ID: 34066020
[TBL] [Abstract][Full Text] [Related]
7. PARP Inhibitors Display Differential Efficacy in Models of
Dickson KA; Xie T; Evenhuis C; Ma Y; Marsh DJ
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445211
[TBL] [Abstract][Full Text] [Related]
8. The emerging role of PARP inhibitors in prostate cancer.
Stellato M; Guadalupi V; Sepe P; Mennitto A; Claps M; Zattarin E; Verzoni E; Valdagni R; De Braud FG; Santini D; Tonini G; Procopio G
Expert Rev Anticancer Ther; 2020 Aug; 20(8):715-726. PubMed ID: 32758032
[TBL] [Abstract][Full Text] [Related]
9. Poly(ADP-ribose) polymerase inhibitors in prostate and urothelial cancer.
Brönimann S; Lemberger U; Bruchbacher A; Shariat SF; Hassler MR
Curr Opin Urol; 2020 Jul; 30(4):519-526. PubMed ID: 32427631
[TBL] [Abstract][Full Text] [Related]
10. Hematological Toxicity of PARP Inhibitors in Metastatic Prostate Cancer Patients with Mutations of BRCA or HRR Genes: A Systematic Review and Safety Meta-analysis.
Maiorano BA; De Giorgi U; Verzoni E; Maiello E; Procopio G; Conteduca V; Di Maio M;
Target Oncol; 2024 Jan; 19(1):1-11. PubMed ID: 37993604
[TBL] [Abstract][Full Text] [Related]
11. Role of Rucaparib in the Treatment of Prostate Cancer: Clinical Perspectives and Considerations.
Wu MS; Goldberg H
Cancer Manag Res; 2022; 14():3159-3174. PubMed ID: 36411744
[TBL] [Abstract][Full Text] [Related]
12. Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis.
Schettini F; Giudici F; Bernocchi O; Sirico M; Corona SP; Giuliano M; Locci M; Paris I; Scambia G; De Placido S; Rescigno P; Prat A; Curigliano G; Generali D
Eur J Cancer; 2021 May; 149():134-152. PubMed ID: 33862496
[TBL] [Abstract][Full Text] [Related]
13. The evolving landscape of PARP inhibitors in castration-resistant prostate cancer: a spotlight on treatment combinations.
Teply BA; Antonarakis ES
Expert Rev Clin Pharmacol; 2022 Nov; 15(11):1293-1304. PubMed ID: 36285641
[TBL] [Abstract][Full Text] [Related]
14. PARP Inhibitors in Ovarian Cancer.
Mittica G; Ghisoni E; Giannone G; Genta S; Aglietta M; Sapino A; Valabrega G
Recent Pat Anticancer Drug Discov; 2018; 13(4):392-410. PubMed ID: 29512470
[TBL] [Abstract][Full Text] [Related]
15. Combining Novel Hormonal Therapies with a Poly (ADP-Ribose) Polymerase Inhibitor for Metastatic Castration-Resistant Prostate Cancer: Emerging Evidence.
Yang J; Xiong X; Zheng W; Liao X; Xu H; Yang L; Wei Q
Curr Oncol; 2023 Dec; 30(12):10311-10324. PubMed ID: 38132385
[TBL] [Abstract][Full Text] [Related]
16. Poly(ADP-ribose) polymerase inhibitors in prostate cancer: a cornerstone in precision oncology.
Ziadeh T; Kourie HR
Pharmacogenomics; 2021 Dec; 22(18):1237-1250. PubMed ID: 34729995
[TBL] [Abstract][Full Text] [Related]
17. Development of a 3D functional assay and identification of biomarkers, predictive for response of high-grade serous ovarian cancer (HGSOC) patients to poly-ADP ribose polymerase inhibitors (PARPis): targeted therapy.
Sheta R; Bachvarova M; Plante M; Renaud MC; Sebastianelli A; Gregoire J; Navarro JM; Perez RB; Masson JY; Bachvarov D
J Transl Med; 2020 Nov; 18(1):439. PubMed ID: 33213473
[TBL] [Abstract][Full Text] [Related]
18. Emerging Role of PARP Inhibitors in Metastatic Prostate Cancer.
Unlu S; Kim JW
Curr Oncol Rep; 2022 Nov; 24(11):1619-1631. PubMed ID: 35931885
[TBL] [Abstract][Full Text] [Related]
19. Targeting Homologous Recombination Deficiency in Ovarian Cancer with PARP Inhibitors: Synthetic Lethal Strategies That Impact Overall Survival.
Xie T; Dickson KA; Yee C; Ma Y; Ford CE; Bowden NA; Marsh DJ
Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230543
[TBL] [Abstract][Full Text] [Related]
20. A Novel Use of Olaparib for the Treatment of Metastatic Castration-Recurrent Prostate Cancer.
Martin GA; Chen AH; Parikh K
Pharmacotherapy; 2017 Nov; 37(11):1406-1414. PubMed ID: 28895177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]